Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hyperglycemia

Hyperglycemia

Part of Postprandial Hyperglycemia

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hyperglycemia

48 trials tracked for Hyperglycemia: 18 in phase 3 or 4 and 4 with published results. The most-cited published study has 422 citations.

48Trials tracked
18Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 15 Phase 3 3 Phase 2 6 Other / NA 24
  1. Phase 4 Insulin for Hyperglycemia in Stroke Trial Completed · 422 cited
  2. Phase 3 Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Completed · 421 cited
  3. Phase 4 Study of Glycemic Control on Liver Transplantation Outcomes Completed · 21 cited
  4. Phase 4 Remifentanil and Glycemic Response in Cardiac Surgery Completed · 19 cited
  5. Phase 4 The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients Completed
  6. Phase 4 Sitagliptin in Non-Diabetic Patients Undergoing General Surgery Completed
Show 42 more trials
  1. Phase 4 Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery Completed
  2. Phase 4 Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients Completed
  3. Phase 4 Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia Completed
  4. Phase 4 A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients Completed
  5. Phase 4 Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes Completed
  6. Phase 4 Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM) Completed
  7. Phase 4 Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin Completed
  8. Phase 4 Diabetes in the Elderly: Prospective Study Completed
  9. Phase 4 Strict Glycemic Control by Insulin Infusion:Observations on Emergency Department Initiation Completed
  10. Phase 4 Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment Completed
  11. Phase 3 Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes Completed
  12. Phase 3 Computerized Glucose Control in Critically Ill Patients Completed
  13. Phase 2 Intravenous Exenatide (Byetta) During Surgery Completed
  14. Phase 2 Glucose Regulation in Acute Stroke Patients (GRASP) Study Completed
  15. Phase 2 Expanding Use of CGM in Critical Care: Impact on Nurse Work Patterns and Patient Outcomes Completed
  16. Phase 2 The Effects of Metformin on Blood Vessel Structure and Function Completed
  17. Phase 2 Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers Completed
  18. Phase 2 Early Insulin and Development of ARDS Completed
  19. N/A Continuous Glucose Monitoring for Hyperglycemia in Critically Ill Patients Completed
  20. N/A The Effect of Tight Glycemic Control on Surgical Site Infection Rates in Patients Undergoing Open Heart Surgery Completed
  21. N/A Feasibility Study to Evaluate Safety and Device Performance of the Hospital Glucose Management System (HGMS) Completed
  22. N/A TPN-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients Completed
  23. N/A MedStar Health Type 2 Diabetes Pathway to Control Completed
  24. N/A Procoagulant Effects of Hyperglycemia After Acute Stroke: A Pilot Study Completed
  25. N/A Glucose and Lipid Metabolism on Antipsychotic Medication Completed
  26. N/A The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes Completed
  27. N/A Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial Completed
  28. N/A Inpatient Closed-loop Glucose Control Completed
  29. N/A Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism Completed
  30. N/A Effectiveness and Cost-Effectiveness of Fully-Automated Digital vs. Human Coach-Based Diabetes Prevention Programs Completed
  31. N/A Intervening in Diabetes With Healthy Eating, Activity, and Linkages To Healthcare - The I-D-HEALTH Study Completed
  32. N/A Green Tea Confections For Managing Postprandial Hyperglycemia-Induced Vascular Endothelial Dysfunction Completed
  33. N/A Comparative Trial Between 3 Types of Insulin Infusion Protocols Completed
  34. N/A Insulin Secretion in Diabetes Before and After Glycemic Control Completed
  35. N/A Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults Completed
  36. N/A SPECS: Safe Pediatric Euglycemia in Cardiac Surgery Completed
  37. N/A Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins Completed
  38. N/A The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose Completed
  39. N/A Hyperglycemia and Mitochondrial Function in The Endothelium of Humans Completed
  40. N/A Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone Completed
  41. N/A Effects of a Complete Diet in Critically Ill Patients With Stress Hyperglycemia Completed
  42. N/A IV Insulin Protocol in Diabetes and Renal Transplantation Completed

Showing the 48 most-cited and recently-updated of 48 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Hyperglycemia: what the trials found

Management of hyperglycemia through various insulin formulations and adjuncts shows varied outcomes in clinical settings. Insulin glargine was evaluated for glycemic control, showing no significant difference in average daily glucose levels or the percentage of participants maintaining target ranges [7, 10]. In a study comparing different insulin regimens (Basal Plus, Basal-bolus, and SSRI), the SSRI group demonstrated significantly fewer hypoglycemia events compared to other regimens 13. Additionally, one trial noted that specific insulin glargine protocols resulted in varying percentages of blood glucose values within target ranges and differing rates of hyperglycemia (>180 mg/dL) 16.

Sitagliptin was evaluated in hospital settings; it was associated with a lower number of patients with mean daily blood glucose >240 mg/dL compared to other groups, and showed no significant difference in the length of stay 12. Sitagliptin also demonstrated a reduction in ICU stay duration 6. Exenatide was shown to significantly reduce median glucose values from steady state through 48 hours or until discharge, while also reducing time to steady state 11. Metformin was utilized in several trials for glycemic management [8, 18, 22], with one study showing significant reductions in HbA1c and fasting plasma glucose (FPG) at 24 weeks 18.

In acute settings, the use of remifentanil was associated with significantly lower instances of blood glucose >180 mg/dL and a reduced requirement for insulin compared to other conditions 4. Intensive IV insulin protocols aimed at maintaining target concentrations did not show significant differences in clinical outcomes like Modified Rankin Scale or NIHSS scores, but were associated with a significant reduction in severe hypoglycemia 17. One study noted that insulin administration was associated with lower infection rates and lower rates of hypoglycemia in specific patient populations 3.

Recent results — preliminary, needs further review

  • Dexcom G6 monitoring showed significantly different percentages of time spent in target glycemic ranges across various groups (p<0.001) 1.
  • Exenatide 0.27 ng/kg/min was evaluated for maintaining intraoperative euglycemia, but the results did not reach statistical significance (p=0.05) 20.

For the clinician treating this condition

  • Sitagliptin is associated with fewer patients reaching high mean daily glucose levels (>240 mg/dL) and shorter ICU stays [6, 12].
  • Exenatide significantly reduces median glucose values and shortens the time to reach a steady state in clinical settings 11.
  • Metformin demonstrates significant reductions in HbA1c and fasting plasma glucose over a 24-week period 18.
  • Intensive IV insulin protocols can reduce the incidence of severe hypoglycemia (blood glucose <40 mg/dL) but do not necessarily improve functional outcomes like NIHSS or Modified Rankin Scale scores 17.

AI synthesis of 11 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Resistance exercise after high-carb meal improves postprandial glucose and endothelial function in healthy adults
Physical Medicine & Rehab RCT
Resistance exercise after high-carb meal improves postprandial glucose and endothelial function in healthy adults When should you exercise after a meal to help your blood vessels?
A randomized crossover study in healthy adults found whole-body resistance exercise performed immediately after a high-carbohydrate meal imp…
Doing a full-body workout right after eating helps healthy adults lower blood sugar and improve blood vessel function better than resting or…
Apr 2, 2026

Questions about Hyperglycemia

Does having marked hyperglycemia increase stroke bleeding risk with bridging therapy?

Yes, marked hyperglycemia (glucose >11.1 mmol/L) significantly increases the risk of parenchymal hematoma (bleeding) when bridging therapy is used instead of direct endovascular thrombectomy for stroke.

Full answer →